Epiomic Epidemiology Series: Aortic Stenosis Forecast in 25 Major Markets 2018–2028

July 2018 | 136 pages | ID: EB8D9957AD8EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Aortic Stenosis in 25 Major Markets

Aortic Stenosis (AS) is the occlusion or loss of aortic valve surface area resulting in stenosis of the aortic valve. Currently, AS is thought to be the most common form of valvular heart disease in Western countries.

This report provides the current prevalent population for AS across 25 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Denmark, Finland, Iceland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the risk factors, aetiology, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AS include:

• Previous myocardial infarct / Angina
• Carotid atherosclerosis
• COPD
• Lower limb atherosclerosis
• Atrial fibrillation
• Heart failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global AS market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of AS and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of AS patients.
• Identification of AS patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of AS patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

MANAGEMENT OF AORTIC VALVE STENOSIS

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

ADDITIONAL DATA

TOP-LINE PREVALENCE FOR AORTIC STENOSIS

FEATURES OF AORTIC STENOSIS PATIENTS

MILD AORTIC STENOSIS

MODERATE AORTIC STENOSIS

SEVERE AORTIC STENOSIS

SYMPTOMATIC

ASYMPTOMATIC

COMORBIDITIES OF AORTIC STENOSIS PATIENTS

MODERATE AORTIC STENOSIS

SEVERE AORTIC STENOSIS

SYMPTOMATIC

ASYMPTOMATIC

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Classification of AS by severity
Table 2. ESC guidelines for management of aortic valve stenosis
Table 3. ACC/AHA guidelines for management of aortic valve stenosis
Table 4. Prevalence of AS, total (000s)
Table 5. Prevalence of AS, males (000s)
Table 6. Prevalence of AS, females (000s)
Table 7. Patients with AS by severity (by valve area—ACC/AHA criteria), total (000s)
Table 8. Patients with AS by aetiology, total (000s)
Table 9. Patients with mild AS by NYHA class, total (000s)
Table 10. Patients with moderate AS by NYHA class, total (000s)
Table 11. Moderate AS patients with a family history of AS, total (000s)
Table 12. Patients with severe AS by presence of symptoms, total (000s)
Table 13. Patients with severe symptomatic AS by NYHA class, total (000s)
Table 14. Patients with severe symptomatic AS by aetiology, total (000s)
Table 15. Patients with severe symptomatic AS by aortic valve structure, total (000s)
Table 16. Severe symptomatic AS patients with a family history of AS, total (000s)
Table 17. Patients with severe asymptomatic AS by NYHA class, total (000s)
Table 18. Patients with severe asymptomatic AS by aetiology, total (000s)
Table 19. Severe asymptomatic AS patients with a family history of AS, total (000s)
Table 20. Moderate AS patients with diabetes, total (000s)
Table 21. Moderate AS patients with arterial hypertension, total (000s)
Table 22. Moderate AS patients with COPD, total (000s)
Table 23. Moderate AS patients with dyslipidaemia, total (000s)
Table 24. Moderate AS patients with atrial fibrillation, total (000s)
Table 25. Moderate AS patients with heart failure, total (000s)
Table 26. Moderate AS patients with lower limb atherosclerosis, total (000s)
Table 27. Moderate AS patients with carotid atherosclerosis, total (000s)
Table 28. Moderate AS patients with a history of myocardial infarction, total (000s)
Table 29. Moderate AS patients with angina, total (000s)
Table 30. Severe symptomatic AS patients with diabetes, total (000s)
Table 31. Severe symptomatic AS patients with arterial hypertension, total (000s)
Table 32. Severe symptomatic AS patients with COPD, total (000s)
Table 33. Severe symptomatic AS patients with dyslipidaemia, total (000s)
Table 34. Severe symptomatic AS patients with atrial fibrillation, total (000s)
Table 35. Severe symptomatic AS patients with heart failure, total (000s)
Table 36. Severe symptomatic AS patients with lower limb atherosclerosis, total (000s)
Table 37. Severe symptomatic AS patients with carotid atherosclerosis, total (000s)
Table 38. Severe symptomatic AS patients with a history of myocardial infarction, total (000s)
Table 39. Severe symptomatic AS patients with angina, total (000s)
Table 40. Severe symptomatic AS patients with coronary artery disease, total (000s)
Table 41. Severe asymptomatic AS patients with diabetes, total (000s)
Table 42. Severe asymptomatic AS patients with arterial hypertension, total (000s)
Table 43. Severe asymptomatic AS patients with COPD, total (000s)
Table 44. Severe asymptomatic AS patients with dyslipidaemia, total (000s)
Table 45. Severe asymptomatic AS patients with atrial fibrillation, total (000s)
Table 46. Severe asymptomatic AS patients with lower limb atherosclerosis, total (000s)
Table 47. Severe asymptomatic AS patients with carotid atherosclerosis, total (000s)
Table 48. Severe asymptomatic AS patients with a history of myocardial infarction, total (000s)
Table 49. Abbreviations and acronyms used in the report
Table 50. USA prevalence of AS by 5-yr age cohort, males (000s)
Table 51. USA prevalence of AS by 5-yr age cohort, females (000s)
Table 52. Canada prevalence of AS by 5-yr age cohort, males (000s)
Table 53. Canada prevalence of AS by 5-yr age cohort, females (000s)
Table 54. France prevalence of AS by 5-yr age cohort, males (000s)
Table 55. France prevalence of AS by 5-yr age cohort, females (000s)
Table 56. Germany prevalence of AS by 5-yr age cohort, males (000s)
Table 57. Germany prevalence of AS by 5-yr age cohort, females (000s)
Table 58. Italy prevalence of AS by 5-yr age cohort, males (000s)
Table 59. Italy prevalence of AS by 5-yr age cohort, females (000s)
Table 60. Spain prevalence of AS by 5-yr age cohort, males (000s)
Table 61. Spain prevalence of AS by 5-yr age cohort, females (000s)
Table 62. UK prevalence of AS by 5-yr age cohort, males (000s)
Table 63. UK prevalence of AS by 5-yr age cohort, females (000s)
Table 64. Poland prevalence of AS by 5-yr age cohort, males (000s)
Table 65. Poland prevalence of AS by 5-yr age cohort, females (000s)
Table 66. Netherlands prevalence of AS by 5-yr age cohort, males (000s)
Table 67. Netherlands prevalence of AS by 5-yr age cohort, females (000s)
Table 68. Norway prevalence of AS by 5-yr age cohort, males (000s)
Table 69. Norway prevalence of AS by 5-yr age cohort, females (000s)
Table 70. Sweden prevalence of AS by 5-yr age cohort, males (000s)
Table 71. Sweden prevalence of AS by 5-yr age cohort, females (000s)
Table 72. Denmark prevalence of AS by 5-yr age cohort, males (000s)
Table 73. Denmark prevalence of AS by 5-yr age cohort, females (000s)
Table 74. Finland prevalence of AS by 5-yr age cohort, males (000s)
Table 75. Finland prevalence of AS by 5-yr age cohort, females (000s)
Table 76. Iceland prevalence of AS by 5-yr age cohort, males (000s)
Table 77. Iceland prevalence of AS by 5-yr age cohort, females (000s)
Table 78. Ireland prevalence of AS by 5-yr age cohort, males (000s)
Table 79. Ireland prevalence of AS by 5-yr age cohort, females (000s)
Table 80. Russia prevalence of AS by 5-yr age cohort, males (000s)
Table 81. Russia prevalence of AS by 5-yr age cohort, females (000s)
Table 82. Turkey prevalence of AS by 5-yr age cohort, males (000s)
Table 83. Turkey prevalence of AS by 5-yr age cohort, females (000s)
Table 84. Japan prevalence of AS by 5-yr age cohort, males (000s)
Table 85. Japan prevalence of AS by 5-yr age cohort, females (000s)
Table 86. China prevalence of AS by 5-yr age cohort, males (000s)
Table 87. China prevalence of AS by 5-yr age cohort, females (000s)
Table 88. South Korea prevalence of AS by 5-yr age cohort, males (000s)
Table 89. South Korea prevalence of AS by 5-yr age cohort, females (000s)
Table 90. India prevalence of AS by 5-yr age cohort, males (000s)
Table 91. India prevalence of AS by 5-yr age cohort, females (000s)
Table 92. Australia prevalence of AS by 5-yr age cohort, males (000s)
Table 93. Australia prevalence of AS by 5-yr age cohort, females (000s)
Table 94. Brazil prevalence of AS by 5-yr age cohort, males (000s)
Table 95. Brazil prevalence of AS by 5-yr age cohort, females (000s)
Table 96. Mexico prevalence of AS by 5-yr age cohort, males (000s)
Table 97. Mexico prevalence of AS by 5-yr age cohort, females (000s)
Table 98. Argentina prevalence of AS by 5-yr age cohort, males (000s)
Table 99. Argentina prevalence of AS by 5-yr age cohort, females (000s)